The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 38 rounds in the feed, most often at Series B and in Biotech.
Over 30 years, ARCH has backed disruptive science companies with as little as $50K to as much as hundreds of millions of dollars, per company.
Venture capitalarchventure.comRounds from 2017-09-18 to ~ 2026-10-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Soufflé Therapeutics A leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives | Series B Verified against 1 of 29 sources | $135M | ~ 2026-10-10 | [ PART ] |
Oratomic Developing neutral atom quantum hardware | Series B |
| $475M |
| 2026-10-08 |
| [ LEAD ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series F Verified against 4 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $275M | 2026-09-09 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series E Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $188M | 2026-08-06 | [ PART ] |
Oratomic Developing neutral atom quantum hardware | Series A Verified against 1 of 11 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $300M | 2026-07-06 | [ LEAD ] |
Trase Trase offers AI-driven solutions for healthcare, government, and enterprise sectors, focusing on enhancing operational efficiencies and data control through specialized AI agents. | Seed Verified against 4 of 12 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $107M | 2026-06-25 | [ PART ] |
Ollin Biosciences Ollin sells innovative therapies targeting serious eye diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $330M | 2026-06-24 | [ LEAD ] |
Prometheus AI startup | Series B Verified against 1 of 15 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12B | 2026-06-11 | [ PART ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series B Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-06-10 | [ PART ] |
CREATE Medicines Create Medicines develops innovative immune programming therapies for treating cancer and autoimmune diseases. | Series B Verified against 2 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $122M | 2026-05-14 | [ LEAD ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2026-01-12 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-20 | [ LEAD ] |
Synchron They build implantable Brain-Computer Interfaces to restore communication and independence for people living with paralysis. | Series D+ Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-11-07 | [ PART ] |
Pelage Pelagepharma develops regenerative medicines focused on treating hair loss using stem cell technology. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-10-15 | [ LEAD ] |
Kardigan Kardigan is a heart health company focused on developing treatments and technologies for cardiovascular diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $254M | 2025-10-14 | [ PART ] |
Ollin Biosciences Ollin sells innovative therapies targeting serious eye diseases for patients. | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-09-17 | [ LEAD ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | ~ 2025-04 | [ PART ] |
Kardigan Kardigan is a heart health company focused on developing treatments and technologies for cardiovascular diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $300M | 2025-01-10 | [ PART ] |
Tenvie Precision-engineered small molecule therapies for neurological and peripheral diseases targeting patients and caregivers. | Funding round Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-08 | [ LEAD ] |
bit.bio A human cell programming company developing technology to produce consistent, scalable human cell models for drug discovery, disease research, functional genomics and toxicology. | Funding round Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $30M | 2024-12-16 | [ PART ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series A Verified against 1 of 6 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2024-07-31 | [ PART ] |
Xaira Therapeutics Xaira Therapeutics sells AI-driven solutions to accelerate drug discovery and development, targeting biopharmaceutical companies and healthcare providers. | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.0B | 2024-04-24 | [ LEAD ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ LEAD ] |
Reserv Reserv provides AI-driven solutions for managing insurance claims, primarily targeting insurance carriers and managing general agents (MGAs). | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $20M | 2023-10-03 | [ PART ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Initial financing Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $30M | 2023-09-19 | [ LEAD ] |
Synchron They build implantable Brain-Computer Interfaces to restore communication and independence for people living with paralysis. | Series C Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2022-12-15 | [ LEAD ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60.8M | 2022-12-05 | [ LEAD ] |
Reserv Reserv provides AI-driven solutions for managing insurance claims, primarily targeting insurance carriers and managing general agents (MGAs). | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $8M | 2022-07-26 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $147.5M | 2022-05-09 | [ PART ] |
bit.bio A human cell programming company developing technology to produce consistent, scalable human cell models for drug discovery, disease research, functional genomics and toxicology. | Series B Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $103M | 2021-11-05 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $50M | 2021-01-07 | [ PART ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series D+ Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2020-07-22 | [ PART ] |
bit.bio A human cell programming company developing technology to produce consistent, scalable human cell models for drug discovery, disease research, functional genomics and toxicology. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $41.5M | 2020-06-13 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2020-04-01 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $6.5M | ~ 2019-12-12 | [ PART ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $104M | 2019-06-26 | [ PART ] |
HiberCell A biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60.8M | ~ 2019-02-07 | [ LEAD ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $55M | 2017-09-18 | [ PART ] |